NCCN Findings on Cancer Drug Shortages
The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading academic cancer centers— has surveyed its Member Institutions multiple times, starting in May 2023, to gauge the impact of ongoing cancer drug shortages. The surveys, conducted by the NCCN Best Practices Committee, continue to shed light on how shortages of cancer treatments not only put a burden on patients, caregivers, and providers, but also how they could delay vital clinical trials and slow the pace of progress for new cancer therapies.
The NCCN Policy and Advocacy team has been involved with national efforts, working with federal regulators, agencies, and lawmakers to implement long-term solutions to drug shortages.